Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (3-o-hexyloxy)-tztp
2. 3-(3-o-hexyl-1,2,5-thiadiazol-4-yl)-1,2,5,6-tetrahydro-1-methylpyridine
3. Ly 246708
4. Ly-246708
5. Ly246708
6. Xanomeline Tartrate
1. 131986-45-3
2. 3-(hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole
3. Ly 246708
4. Ly-246708
5. Ly246708
6. 3-hexoxy-4-(1-methyl-3,6-dihydro-2h-pyridin-5-yl)-1,2,5-thiadiazole
7. 9ori6l73cj
8. Chembl21536
9. 5-(4-hexyloxy-[1,2,5]thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydro-pyridine
10. Chebi:10056
11. Ly-246708 Free Base
12. 5-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
13. Xanomeline (usan)
14. Xanomeline [usan]
15. Pyridine, 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-
16. Xanomeline [usan:inn]
17. Unii-9ori6l73cj
18. Lumeron
19. Memcor
20. Hexyloxy-tztp
21. Pyridine, 3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-
22. Xanomeline [mi]
23. Xanomeline [inn]
24. Gtpl57
25. 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine
26. Xanomeline [mart.]
27. Xanomeline [who-dd]
28. Schembl121046
29. Dtxsid60157286
30. Bcp31492
31. Ex-a6592
32. Zinc1532358
33. Bdbm50003359
34. Mfcd00867179
35. Akos016007489
36. Db15357
37. Sb18821
38. Nnc-11-0232
39. Ds-15663
40. Hy-105182
41. Cs-0025224
42. Ft-0602214
43. C72296
44. D06330
45. A888347
46. L000694
47. Q8042940
48. Ly-246708; Ly246708; Ly 246708
49. 3-(4-hexoxy-1,2,5-thiadiazol-3-yl)-1-methyl-5,6-dihydro-2h-pyridine
50. 3-(4-hexyloxy-1 ,2,5-thiadiazol-3-yl)-1 ,2,5,6-tetrahydro-1-methyl-pyridine
51. 5-(4-hexyloxy-[1,2,5]thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydro-pyridine; Oxalic Acid
52. 5-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine, Aldrichcpr
53. 1018845-70-9
Molecular Weight | 281.42 g/mol |
---|---|
Molecular Formula | C14H23N3OS |
XLogP3 | 3.3 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 7 |
Exact Mass | 281.15618354 g/mol |
Monoisotopic Mass | 281.15618354 g/mol |
Topological Polar Surface Area | 66.5 Ų |
Heavy Atom Count | 19 |
Formal Charge | 0 |
Complexity | 298 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Muscarinic Agonists
Drugs that bind to and activate muscarinic cholinergic receptors (RECEPTORS, MUSCARINIC). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (See all compounds classified as Muscarinic Agonists.)
Parasympathomimetics
Drugs that mimic the effects of parasympathetic nervous system activity. Included here are drugs that directly stimulate muscarinic receptors and drugs that potentiate cholinergic activity, usually by slowing the breakdown of acetylcholine (CHOLINESTERASE INHIBITORS). Drugs that stimulate both sympathetic and parasympathetic postganglionic neurons (GANGLIONIC STIMULANTS) are not included here. (See all compounds classified as Parasympathomimetics.)
Psychotropic Drugs
A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). (See all compounds classified as Psychotropic Drugs.)
NDC Package Code : 58032-3003
Start Marketing Date : 2023-03-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2024
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2024
Details:
Through the acquisition, BMS will enhance the development of KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of being a first-in-class M1 / M4 muscarinic receptor agonist, with differentiated efficacy and safety for treating schizophrenia in adults.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Bristol Myers Squibb
Deal Size: $14,000.0 million Upfront Cash: $14,000.0 million
Deal Type: Acquisition March 18, 2024
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : $14,000.0 million
Deal Type : Acquisition
Details : Through the acquisition, BMS will enhance the development of KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of being a first-in-class M1 / M4 muscarinic receptor agonist, with differentiated efficacy and safety for treating schizoph...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : $14,000.0 million
March 18, 2024
Details:
Through the acquisition, BMS will enhance the development of KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of being a first-in-class M1 / M4 muscarinic receptor agonist, with differentiated efficacy and safety for treating schizophrenia in adults.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Bristol Myers Squibb
Deal Size: $14,000.0 million Upfront Cash: $14,000.0 million
Deal Type: Acquisition December 22, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bristol Myers Squibb
Deal Size : $14,000.0 million
Deal Type : Acquisition
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Details : Through the acquisition, BMS will enhance the development of KarXT (xanomeline-trospium), an antipsychotic with a novel mechanism of being a first-in-class M1 / M4 muscarinic receptor agonist, with differentiated efficacy and safety for treating schizoph...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : $14,000.0 million
December 22, 2023
Details:
KarXT (xanomeline and trospium chloride) is an M1/M4 receptor Agonist small molecule drug delivered orally in capsule form for the treatment of Schizophrenia.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline and trospium chloride) is an M1/M4 receptor Agonist small molecule drug delivered orally in capsule form for the treatment of Schizophrenia.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 29, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 17, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 16, 2023
Details:
KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Karuna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Karuna Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
Details : KarXT (xanomeline-trospium) is an oral, investigational M1/M4-preferring muscarinic agonist in development for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer’s disease.
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2023
Details:
The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclinical programs.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $460.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 24, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $460.0 million
Deal Type : Public Offering
Details : The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclini...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 24, 2023
Details:
Under the agreement, Royalty Pharma will acquire PureTech’s royalty in Karuna’s KarXT (xanomeline), an oral, investigational M1/M4-preferring muscarinic agonist for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Royalty Pharma
Deal Size: $500.0 million Upfront Cash: $100.0 million
Deal Type: Agreement March 23, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : $500.0 million
Deal Type : Agreement
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
Details : Under the agreement, Royalty Pharma will acquire PureTech’s royalty in Karuna’s KarXT (xanomeline), an oral, investigational M1/M4-preferring muscarinic agonist for the treatment of psychiatric and neurological conditions, including schizophrenia and...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : $100.0 million
March 23, 2023
Details:
The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclinical programs.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Brand Name: KarXT
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Goldman Sachs & Co. LLC
Deal Size: $400.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 21, 2023
Lead Product(s) : Xanomeline,Trospium Chloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Goldman Sachs & Co. LLC
Deal Size : $400.0 million
Deal Type : Public Offering
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
Details : The proceedings will be used to fund Karuna's ongoing and planned clinical trials of KarXT (xanomeline), to support the potential commercialization of KarXT for psychosis in schizophrenia, to support and expand company's pipeline of clinical and preclini...
Brand Name : KarXT
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 21, 2023
22 May 2024
// Andrea Park FIERCE PHARMA
https://www.fiercepharma.com/marketing/bms-taps-taye-diggs-its-best-man-schizophrenia-educational-campaign
20 May 2024
// BUSINESSWIRE
21 Mar 2023
// BIOPHARMADIVE
https://www.biopharmadive.com/news/karuna-schizophrenia-emergent-3-trial-karxt/645392/#:~:text=The%20results%20add%20to%20a,living%20with%20the%20brain%20disorder.&text=An%20experimental%20drug%20from%20Karuna,a%20potential%20therapy%20for%20schizophrenia.
23 Aug 2022
// BUSINESSWIRE
10 Aug 2022
// PHARMA FILE
http://www.pharmafile.com/news/722654/karuna-therapeutics-announces-positive-results-phase-iii-trial-schizophrenia
08 Aug 2022
// BUSINESS WIRE
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?